For instance, MYRF-AS1 was associated with genomic instability and is considered a risk factor in Non-small cell lung cancer [81], while PRANCR is up-regulated in primary ovarian cancer [82] and SCL25A5-AS1 was associated with the bladder cancer growth [83]. Here, MYRF is linked to urinary bladder cancer.